A Phase 1 clinical trial for a domestically developed 4th generation non-small cell lung cancer (NSCLC) drug has been approved in Korea.

The Ministry of Food and Drug Safety approved the Phase I trial for Oncobix’s oral ALK/EGFR inhibitor 'OBX02-011' on patients with advanced NSCLC on the 12th.

The trial will be conducted at the National Cancer Center and will include dose escalation and dose expansion testing in the first-in-human Phase 1 trial.

According to Oncobix, epidermal growth factor receptor (EGFR) mutations are one of the leading causes of NSCLC that account for approximately 10-30% of NSCLC, which is why an urgent need remains for the development of therapies t